U.S. Semiconductors Stock News

NasdaqGS:MCHP
NasdaqGS:MCHPSemiconductor

US Stock Market Today: S&P 500 Futures Dip amid Cooling Jobs, Mixed Soft-Landing Hopes

The Morning Bull - US Market Morning Update Thursday, Dec, 4 2025 US stock futures are slightly softer this morning, as investors juggle strong signals from the services side of the economy with a surprise cooling in hiring. A key health check on the services sector came in at 52.6 in November, showing businesses are still growing and prices are rising more slowly, which helps the case for steady growth without runaway inflation. But a separate jobs report showed private payrolls dropping by...
NYSE:CXM
NYSE:CXMSoftware

Sprinklr (CXM) Net Margin Strengthens, Challenging Market Skepticism on Slower Revenue Growth

Sprinklr (CXM) has just posted another quarter of solid top line and bottom line numbers, with Q2 2026 revenue at about $212 million and basic EPS of roughly $0.05, supported by trailing 12 month revenue of about $821 million and EPS of around $0.47. The company has seen revenue move from roughly $196 million in Q1 2025 to about $212 million in Q2 2026, while basic EPS has ranged from about $0.04 in Q1 2025 to approximately $0.05 in the latest quarter. This sets up a story where profitability...
NasdaqGS:BDTX
NasdaqGS:BDTXBiotechs

Black Diamond Therapeutics (BDTX): Valuation Check After New Phase 2 Silevertinib Data and Glioblastoma Trial Plans

Black Diamond Therapeutics (BDTX) just released topline Phase 2 data for its EGFR inhibitor silevertinib in frontline non small cell lung cancer, while also laying out plans for a randomized Phase 2 trial in newly diagnosed glioblastoma. See our latest analysis for Black Diamond Therapeutics. The latest silevertinib update landed against a choppy backdrop for Black Diamond Therapeutics, with a sharp 1 day share price return of negative 22.03 percent and a 7 day share price return of negative...
NYSE:K
NYSE:KFood

Does Kellanova’s Snacks Focus Justify Its Strong Multi Year Share Price Gains?

Wondering if Kellanova is still fairly priced after its long run, or if there is more upside left in the tank? This breakdown will help you decide whether the current share price actually makes sense. The stock has been mostly treading water in the short term, down 0.6% over the last week and roughly flat over the past month at 0.1%. However, that hides a steadier climb of 2.6% year to date and 6.2% over the last year, compounding into 32.5% and 69.5% gains over the past 3 and 5...
NYSE:TJX
NYSE:TJXSpecialty Retail

TJX (TJX) Q3: Strong 5% Same-Store Sales Growth Tests Justification for Premium Valuation

TJX Companies (TJX) just posted another solid quarter, with Q3 2026 revenue of about $15.1 billion, Basic EPS of $1.28, and net income of $1.4 billion setting the tone for its latest update. The company has seen revenue move from roughly $14.1 billion and EPS of $1.15 in Q3 2025 to $15.1 billion and $1.28 this quarter, while trailing twelve month revenue has climbed to about $59.0 billion alongside EPS of $4.58 and net income of $5.1 billion, giving investors a clear view of steady top and...
NasdaqGM:TBPH
NasdaqGM:TBPHPharmaceuticals

Is Oppenheimer’s Focus on Ampreloxetine Quietly Redefining Theravance Biopharma’s (TBPH) Risk-Reward Profile?

Oppenheimer recently initiated coverage on Theravance Biopharma with an Outperform rating, emphasizing the importance of the Phase 3 ampreloxetine readout expected in the first quarter of 2026 and the company’s virtual key opinion leader event on this program. The focus on ampreloxetine as a potential billion-dollar therapy in a rare neurogenic condition highlights how pivotal this single late-stage asset has become for Theravance’s future prospects and risk profile. We’ll now explore how...